開發Nectin-4標靶之溶瘤麻疹病毒療法作為乳癌及肝癌治療

English | 正體中文 | 简体中文 | 全文筆數/總筆數 : 45422/58598 (78%)
造訪人次 : 2511979 線上人數 : 289

RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.

Taipei Medical University Institutional Repository > 醫學院 > 醫學科學研究所 > 博碩士論文 > Item 987654321/61465

請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/61465

題名:	開發Nectin-4標靶之溶瘤麻疹病毒療法作為乳癌及肝癌治療 Development of Nectin-4-Targeting Oncolytic Measles Virotherapy for the Treatment of Breast and Liver Cancers
作者:	劉卿宣 LIU, CHING-HSUAN
貢獻者:	醫學科學研究所博士班 RICHARDSON, CHRISTOPHER 林良宗
關鍵詞:	Measles virus;Oncolytic virotherapy;Breast cancer;Liver cancer;Camptothecin;Ursolic acid;Nanoparticles;Chemovirotherapeutic;Nectin-4
日期:	2021-07-14
上傳時間:	2022-03-16 22:44:56 (UTC+8)
摘要:	Oncolytic viruses (OVs) are a rapidly emerging treatment platform for various types of cancer that offers several advantages over conventional anticancer therapeutics, including selectivity, potency, and targeted cell death. Recent studies have revealed that measles virus (MV), a member of the Paramyxoviridae family, possesses the ability to selectively target carcinomas by recognizing the tumor cell marker nectin-4, which is highly expressed in many types of cancer. Specifically, wild-type MV targets nectin-4 on the tumor cells and does not engage CD46, which is an additional receptor expressed on all nucleated cells and employed by vaccine strains of MV for infection. The use of MV-based vectors with wild-type glycoproteins is thus justified as candidate for potential development as an oncolytic agent targeting nectin-4. The results in this thesis present as proof-of-concept, the use of a recombinant wild-type MV as an oncolytic agent to effectively target nectin-4-marked cancers, and demonstrate its ability to induce oncolysis of nectin-4-expressing breast and hepatocellular carcinoma (HCC) tumor cells. Specifically, it was observed that MV could dose-dependently and efficiently target and induce cytotoxicity in both cancer models. In addition, the data also demonstrate the feasibility to use a combination of chemotherapeutic agents or anticancer nanoparticles as a chemovirotherapeutic approach to enhance MV’s oncolytic efficacy, while reducing the doses of treatment required and potentially increasing its safety. Results from this study underpin the oncolytic potential of recombinant MV and support the future development of oncolytic virotherapy using MV-based vectors for the management of nectin-4-expressing cancers.
描述:	博士指導教授：RICHARDSON, CHRISTOPHER 指導教授：林良宗委員：DUNCAN, ROY 委員：GUJAR, SHASHI 委員：LICHTY, BRIAN
資料類型:	thesis
顯示於類別:	[醫學科學研究所] 博碩士論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	122	檢視/開啟

檢視Licence

在TMUIR中所有的資料項目都受到原著作權保護.

TAIR相關文章

著作權聲明 Copyright Notice

本平台之數位內容為臺北醫學大學所收錄之機構典藏，包含體系內各式學術著作及學術產出。秉持開放取用的精神，提供使用者進行資料檢索、下載與取用，惟仍請適度、合理地於合法範圍內使用本平台之內容，以尊重著作權人之權益。商業上之利用，請先取得著作權人之授權。
The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.
瀏覽或使用本平台，視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例，並不得為任何不法目的使用TMUIR。
By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.
本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者，煩請權利人通知本平台維護人員([email protected])，將立即採取移除該數位著作等補救措施。
TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

資料載入中.....